PFE May BE Getting Ready To Acquire BMY
According to rumors on message boards, Bristol-Myers Squib may be at the center of one of the biggest takeovers of the year relatively soon. According to the rumors, the company is currently in talks to be taken over by Pfizer Inc. (NYSE: PFE).
The rumors don’t mention any price or premium that may be paid to take the company over. Nonetheless, they do suggest that PFE and BMY are in active talks, working to hammer out a deal. According to the rumors, the talks are in advanced stages and a deal may be announced as soon as tomorrow morning.
The rumors make sense too. Pfizer has been very outspoken about plans to turn the company around. Part of these plans has to do with accretive acquisitions of other companies in the pharmaceuticals space.
Of course, BMY isn’t going to come with a small price tag, but should a deal be signed, the price tag would likely be worth it. After all, the company has a long list of commercial-stage assets and products under development that fall right into Pfizer’s wheelhouse.
Considering the fact that Pfizer is actively working to improve value for investors and that BMY offers up quite a bit of value, there’s a chance that this rumor may be hitting the nail on the head soon.
According to rumors on message boards, Bristol-Myers Squib may be at the center of one of the biggest takeovers of the year relatively soon. According to the rumors, the company is currently in talks to be taken over by Pfizer Inc. (NYSE: PFE).
The rumors don’t mention any price or premium that may be paid to take the company over. Nonetheless, they do suggest that PFE and BMY are in active talks, working to hammer out a deal. According to the rumors, the talks are in advanced stages and a deal may be announced as soon as tomorrow morning.
The rumors make sense too. Pfizer has been very outspoken about plans to turn the company around. Part of these plans has to do with accretive acquisitions of other companies in the pharmaceuticals space.
Of course, BMY isn’t going to come with a small price tag, but should a deal be signed, the price tag would likely be worth it. After all, the company has a long list of commercial-stage assets and products under development that fall right into Pfizer’s wheelhouse.
Considering the fact that Pfizer is actively working to improve value for investors and that BMY offers up quite a bit of value, there’s a chance that this rumor may be hitting the nail on the head soon.